Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib +/- Gemcitabine in Metastatic Pancreatic Cancer
NCT00114244Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2004
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sorafenib in pancreatic carcinoma (2 arms), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate. Started Dec 2004; status: completed.
02
Drugs
sorafenib
03
Conditions
pancreatic carcinoma
Beyond the preview
Go deeper on NCT00114244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00114244.